The purpose of the Protein Chemistry and Proteomics Shared Resource is to provide essential services in peptide synthesis, protein separation, electrophoresis, protein identification, mass spectrometry, differential proteomics, biomarker discovery, small molecule analysis and peptide quantification, computing informatics and in silico molecular modeling to Cancer Center members. This is accomplished by providing state-of-theart services, expertise and technologies. Services include: (1) Solid phase peptide synthesis by Fmoc orthogonal chemistry;(2) Synthesis of peptide/protein specific immunogens;(3) Protein separation by reverse phase HPLC and FPLC methods;(4) one-dimensional (1-D) and 2-dimensional (2-D) PAGE of protein mixtures including DIGE separation and analysis;(5) Edman chemical sequencing;(6) Protein identification by nanoLC-MS/MS methods;(7) Differential Proteomics / Biomarker discovery by tandem MS and targeted MS (e.g., MRM) methods;(8) Small molecule analysis by LC-MS and MRM methods;(9) Protein PTM analysis by nanoLC-FT-ICR mass spectrometry, and (10) Computational services for peptide design, de novo modeling of proteins, protein identification, and differential proteomics using iTRAQ and label-free methods. Future plans of the shared resource will include the development of Electron Transfer Dissociation (ETD) mass spectrometry for efficient mapping of protein post-translational modifications and chemical peptide ligation synthesis utilizing thioester methods for the chemical synthesis of small proteins and polypeptides. Cancer Center member use of the Shared Resource has increased by nearly 38% over this grant period, to more than 97 members in 2007. Cancer Center use represents 65% of the total services provided by the Shared Resource. The Protein Chemistry and Proteomics Shared Resource has been vital to Cancer Center members supporting a broad array of peer review funded research that has produced more than 400 publications during the current funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465660
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$253,924
Indirect Cost
$78,134
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications